With the development of multi-omics technology, precision medicine is becoming a reality. The data show that biomarker-driven clinical trials have higher success rates, due to their accurate targeting ability.
Therefore, how to identify potential biomarkers earlier in preclinical studies, through better experimental design and powerful bioinformatics data analysis, has become a hot topic.
In our webinar, we use case studies to demonstrate how to identify potential biomarkers at the preclinical study stage via in vitro and in vivo screening.
Dr. Linda Xue, Principal Scientist, Crown Bioscience
Dr. Linda Xue joined Crown Bioscience in 2015 and is currently a Principal Scientist in the Data Science and Bioinformatics division. Her expertise surrounds the areas of tumor model genomics, biomarker discovery and, NGS product design and software development.
Dr. Xue received her Ph.D. in Molecular Biomedicine and M.Sc. in Life Science Informatics from University of Bonn in Germany, and her B.Sc. in Bioengineering from Beihang University.